Deuterium Capital Management’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Deuterium Capital Management’s Portfolio PRTK Stock Details PRTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-55,136	Closed	-$122K	–	112
2023 Q2	$122K	Buy	+55,136	New	+$114K	0.16%	86

Deuterium Capital Management's PRTK Position: Q3 2023 in Review

Deuterium Capital Management sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2023, closing a stake of 55,136 shares — an estimated $122K sold.

Deuterium Capital Management first reported a position in PRTK in Q2 2023 and held it in 1 quarter. The position peaked at $122K in Q2 2023. 0 funds tracked by Wall St. Rank hold PRTK as of Q3 2023.

Deuterium Capital Management reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
Deuterium Capital Management sold 55,136 Paratek Pharmaceuticals, Inc. shares in Q3 2023, an estimated $122K.
Deuterium Capital Management first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2023 and held it in 1 quarter.
Deuterium Capital Management's Paratek Pharmaceuticals, Inc. position peaked at $122K in Q2 2023.
0 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2023.

Based on Deuterium Capital Management's 13F filing for Q3 2023, filed 31 Oct 2023.